Brief: Moberg Pharma And Cipher Pharmaceuticals Sign Exclusive License Agreement For Mob-015 In Canada
Sept 18 (Reuters) - Moberg Pharma Ab (Publ) MBPH.ST :
* MOBERG PHARMA AND CIPHER PHARMACEUTICALS SIGN EXCLUSIVE
LICENSE
AGREEMENT FOR MOB-015 IN CANADA
* SAYS UNDER AGREEMENT, MOBERG PHARMA IS ELIGIBLE TO RECEIVE
USD
14.6 MILLION IN ONE-TIME PAYMENTS AND MILESTONES, AS WELL AS
ROYALTIES ON NET SALES IN CANADA
Source text for Eikon: ID:nWkr368F53
Further company coverage: MBPH.ST
(Reporting by Stockholm Newsroom)
((stockholm.newsroom@thomsonreuters.com; +4687001017;))
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million